Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
Provided By GlobeNewswire
Last update: Aug 7, 2025
BOSTON and SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the second quarter ending June 30, 2025, and provided a business update.
Read more at globenewswire.com
